Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis - PubMed (original) (raw)

Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis

Mohammad Salajegheh et al. Muscle Nerve. 2009 Jul.

Abstract

The nucleic acid binding protein TDP-43 was recently identified in normal myonuclei and in the sarcoplasm of inclusion body myositis (IBM) muscle. Here we found TDP-43 sarcoplasmic immunoreactivity in 23% of IBM myofibers, while other reported IBM biomarkers were less frequent, with rimmed vacuoles in 2.8%, fluorescent Congo red material in 0.57%, SMI-31 immunoreactivity in 0.83%, and focal R1282 beta-amyloid immunoreactivity in 0.00% of myofibers. The presence of as little as >1% of myofibers with nonnuclear sarcoplasmic TDP-43 was highly sensitive (91%) and specific (100%) to IBM among 50 inflammatory myopathy patient samples, although some patients with hereditary inclusion body myopathies and myofibrillar myopathy also had sarcoplasmic TDP-43. TDP-43 mutations were sought, and none were identified. TDP-43 could be one of many nucleic acid binding proteins that are abnormally present in IBM sarcoplasm. They could potentially interfere with the normal function of extranuclear RNAs that maintain myofiber protein production.

PubMed Disclaimer

Figures

Figure 1

Figure 1. Normal myonuclear localization of TDP-43

(A,B) TDP-43 light microscopic images. The pattern of staining suggests nuclear localization and colocalization with DNA staining methyl green confirms this. (C1−3) Colocalization of TDP-43, SMI-31, and DAPI in a single normal muscle section with triple immunofluorescent studies further confirms nuclear localization of both of these proteins. (D1−4) TDP-43 localizes internally to the nuclear membrane as shown in triple immunofluorescent studies with the nuclear membrane protein emerin and DAPI.

Figure 2

Figure 2. Relationship of sarcoplasmic TDP-43 immunoreactivity to other features

(A1-A3) Adjacent sections from an IBM sample show sarcoplasmic areas of intense TDP-43 staining that are not immunoreactive for SMI31 and do not show fluorescence after Congo red staining. (B1-B3) Adjacent sections from an IBM sample show TDP-43 sarcoplasmic staining distinct from SMI31 and DAPI nuclear staining. (C,D) High magnification of TDP-43 immunoreactivity in a myofiber from IBM, with adjacent section showing H&E appearance of this myofiber.

Figure 3

Figure 3. Paired H&E and TDP-43 images from IBM sections

(A-B) TDP-43 sarcoplasmic distribution occurs in non-necrotic myofibers that may have mild abnormalities (enlarged rounded fiber #1; small or angulated fibers #2 and #3) or (C) substantial abnormalities (many slightly basophilic small fibers, some with enlarged nuclei; the vacuolated fiber #4) present on H&E staining.

Figure 4

Figure 4. Rimmed vacuole lining reactive with anti-TDP-43, SMI-31, and DAPI in IBM muscle

(A1-A3) Triple stained immunofluorescent section shows vacuoles lined with reactivities for TDP-43, SMI-31, and DAPI. The arrow indicates a myofiber with sarcoplasmic TDP-43, whose nucleus (identified by SMI31 and DAPI staining) does not contain visible TDP-43. (B) Higher magnification of panel A-1, outlining TDP-43 lined vacuoles (arrowheads) and a myofiber with sarcoplasmic non-nuclear TDP-43 (arrow).

Figure 5

Figure 5. Myofibers with sarcoplasmic TDP-43 typically show absent nuclear TDP-43 staining

(A1−3) A triangular fiber #1 shows abundant sarcoplasmic linear TDP-43 accumulation. Nuclei (marked with arrowheads) are devoid of TDP-43. In contrast, the adjacent rounded myofiber #2 lacks sarcoplasmic accumulation and has normal TDP-43 nuclear immunoreactivity (arrows). Inflammatory cells are present between the two fibers. (B1−3) TDP-43 sometimes clusters around myonuclei (arrowheads) in addition to multifocally within the sarcoplasm. A-1 and B-1 are merged images of TDP-43 (A-2 and B-2) and DAPI (A-3 and B-3) fluorescent signals.

Figure 6

Figure 6. TDP-43 immunoblots of inflammatory myopathy and normal muscle

Immunoblots probed with either secondary anti-IgG antibody only (no primary antibody) or antibodies against TDP-43 or actin followed by secondary anti-IgG antibodies. Sample ID for each lane labeled in the bottom panel. An approximately 43 kDa band at the appropriate molecular weight for TDP-43 (black arrow) is seen in all muscle samples and was larger in all IBM samples, despite slightly less actin, than in other inflammatory myopathy samples (DM = dermatomyositis; NM = necrotizing myopathy, PM = polymyositis). The interpretation of the additional band previously reported in IBM muscle at approximately 50 kDa (white arrow) is confounded by the presence of abundant immunoglobulin heavy chains present in IBM muscle also at this molecular weight, as shown in the 1st lane stained only with secondary anti-IgG, without primary anti-TDP-43 antibody. TDP-43 immunoreactivity beyond IgG immunoreactivity may be present at this weight (compare sample 372 without and with primary antibody) but is not disease-specific, as it is present in DM, NM, and PM samples. Immunoreactivity at all other weights also appeared to be not disease-specific, except for 2 IBM samples (354 and 372) that showed greater intensity of multiple lower molecular weight TDP-43 fragments (*).

Figure 7

Figure 7

Comparison of sarcoplasmic TDP-43 abnormalities with other IBM histopathological biomarkers.

References

    1. Askanas V, Engel WK, Alvarez RB. Light and electron microscopic localization of beta-amyloid protein in muscle biopsies of patients with inclusion-body myositis. Am J Pathol. 1992;141(1):31–36. - PMC - PubMed
    1. Askanas V, Engel WK, Alvarez RB, Glenner GG. beta-Amyloid protein immunoreactivity in muscle of patients with inclusion-body myositis. Lancet. 1992;339(8792):560–561. - PubMed
    1. Askanas V, Alvarez RB, Engel WK. beta-Amyloid precursor epitopes in muscle fibers of inclusion body myositis. Ann Neurol. 1993;34(4):551–560. - PubMed
    1. Askanas V, Engel WK, Alvarez RB. Enhanced detection of congo-red-positive amyloid deposits in muscle fibers of inclusion body myositis and brain of Alzheimer's disease using fluorescence technique. Neurology. 1993;43(6):1265–1267. - PubMed
    1. Ayala YM, Zago P, D'Ambrogio A, Xu YF, Petrucelli L, Buratti E, Baralle FE. Structural determinants of the cellular localization and shuttling of TDP-43. J Cell Sci. 2008;121(Pt 22):3778–3785. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources